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Abstract
Background: To elucidate the genes involved in the neoplastic transformation of B cells, global
gene expression profiles were generated using Affymetrix U74Av2 microarrays, containing 12,488
genes, for four different groups of mouse B-cell lymphomas and six subtypes of pristane-induced
mouse plasma cell tumors, three of which developed much earlier than the others.
Results: Unsupervised hierarchical cluster analysis exhibited two main sub-clusters of samples: a
B-cell lymphoma cluster and a plasma cell tumor cluster with subclusters reflecting mechanism of
induction. This report represents the first step in using global gene expression to investigate
molecular signatures related to the role of cooperating oncogenes in a model of Myc-induced
carcinogenesis. Within a single subgroup, e.g., ABPCs, plasma cell tumors that contained typical
T(12;15) chromosomal translocations did not display gene expression patterns distinct from those
with variant T(6;15) translocations, in which the breakpoint was in the Pvt-1 locus, 230 kb 3' of c-
Myc, suggesting that c-Myc activation was the initiating factor in both. When integrated with
previously published Affymetrix array data from human multiple myelomas, the IL-6-transgenic
subset of mouse plasma cell tumors clustered more closely with MM1 subsets of human myelomas,
slow-appearing plasma cell tumors clustered together with MM2, while plasma cell tumors
accelerated by v-Abl clustered with the more aggressive MM3-MM4 myeloma subsets. Slow-
appearing plasma cell tumors expressed Socs1 and Socs2 but v-Abl-accelerated plasma cell tumors
expressed 4–5 times as much. Both v-Abl-accelerated and non-v-Abl-associated tumors exhibited
phosphorylated STAT 1 and 3, but only v-Abl-accelerated plasma cell tumors lost viability and
STAT 1 and 3 phosphorylation when cultured in the presence of the v-Abl kinase inhibitor, STI-
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571. These data suggest that the Jak/Stat pathway was critical in the transformation acceleration by
v-Abl and that v-Abl activity remained essential throughout the life of the tumors, not just in their
acceleration. A different pathway appears to predominate in the more slowly arising plasma cell
tumors.
Conclusion: Gene expression profiling differentiates not only B-cell lymphomas from plasma cell
tumors but also distinguishes slow from accelerated plasma cell tumors. These data and those
obtained from the sensitivity of v-Abl-accelerated plasma cell tumors and their phosphorylated
STAT proteins indicate that these similar tumors utilize different signaling pathways but share a
common initiating genetic lesion, a c-Myc-activating chromosome translocation.
Background
Since the discovery that BALB/c mice predictably develop
plasma cell tumors (PCTs) following the induction of
intraperitoneal (ip) inflammatory granulomas by
implanting plastic objects or injecting mineral oil or sili-
cones, this model has been a valuable experimental sys-
tem for studying plasma cell neoplasia [1]. The ip
inflammatory tissue produces interleukin 6 (IL-6), insu-
lin-like growth factor 1 (IGF1), and other cytokines that
support the growth of TEPC-type PCTs that appear slowly,
starting no earlier than 120 days after ip pristane injec-
tion. Infection with retroviruses containing oncogenes,
e.g., Abelson Virus (v-Abl [2]), J3V1 virus (v-Raf plus v-
Myc [3]), RIM virus (v-Ha-Ras plus c-Myc [4]), ABLMYC
Virus (v-Abl plus c-Myc [5]), accelerates PCT formation,
producing ABPC, J3PCs, RIMPCs and ABLMYCPCs,
respectively, in as little as 12 days (see Figure 1A and Table
1). It has never been tested whether continued activity of
these accelerating oncogenes was required subsequent to
completion of transformation. iMycEµ (Myc/IgH-knock-
in) BALB/c mice and IL-6-transgenic BALB/c mice also
develop intraperitoneal PCTs iMycEµ PCs [6] and KiPCs
[7], respectively, at a slightly accelerated rate following
pristane injection. IL-6-transgenic BALB/c mice spontane-
ously develop PCTs in lymph nodes (IL6PCs [8]) but with
latent periods no shorter than TEPCs. As with human
multiple myeloma (MM), most of the tumors in the dif-
ferent groups of PCTs consist of neoplasms of plasma cells
that are morphologically indistinguishable, although the
cells in the accelerated tumors occasionally appear larger
and more blastic. Other forms of B-cell lymphomas (BCL)
also appear in the lymph nodes of iMyc mice, BCLEµ [9]
and BCLCα [10].
Chromosomal translocations that deregulate expression
of the proto-oncogene c-Myc constitute the earliest known
tumorigenic step in PCT formation. More than 95% of
PCTs, have chromosomal translocations, either the typical
(85% of PCTs) T(12;15) or variants (15% of PCTs)
T(6;15) or T(15;16) [11-13]. T(12;15) joins the immu-
noglobulin heavy chain locus and its strong enhancers to
different regions: within the c-Myc  locus (Class I) or
upstream of it (Class II). T(6;15) joins the immunoglobu-
lin kappa light chain locus with its enhancers to a site in
the Pvt1 locus, between 200 and 300 kb 3' of the c-Myc
locus [1,11]. Myc activation appears to be the hallmark of
all typical BALB/c PCTs, presumably via Ig enhancer inser-
tion near c-Myc. It has been assumed that the variant
translocations also contribute to the transformation of
plasma cells by upregulating c-Myc by some mechanism
akin to but different from the 12;15 translocations. This
notion has never been experimentally validated.
To investigate the mechanisms underlying Myc-induced B-
cell neoplasia (particularly PCTs) in BALB/c mice, gene
expression profiles for four groups of BCLs and for PCTs
from six different induction protocols (Table 1) were gen-
erated. The analysis of the microarray gene expression
data focused on four questions: 1) which genes differenti-
ate BCLs from PCTs; 2) which genes and pathways are
involved in PCT acceleration by the v-Abl oncogene; 3) are
there genes that differ between PCTs induced by typical
and variant c-Myc-activating chromosomal translocations;
4) how much similarity in gene expression profiles exists
between mouse PCTs and human MMs? To answer the
final question, a meta-analysis was performed by combin-
ing our mouse tumor expression data with data published
for human multiple myelomas to determine similarities
and differences between these plasma cell tumors in dif-
ferent species.
Results
Unsupervised clustering yielded two main clusters: B cell 
lymphoma cluster and plasma cell tumor cluster
To assess the relative similarities or dissimilarities in glo-
bal gene expression patterns from six different subtypes of
mouse PCT (PCT-1 – PCT-6, Table 1) and four different
groups of mouse BCL (BCL-1 – BCL-4, Table 1), we first
applied unsupervised hierarchical cluster analysis using
correlation-based average linkage clustering. Characteris-
tic expression signatures were searched for among the
6424 genes remaining after filtering out genes showing
more than 50% absence (A) calls among the 70 RNA sam-
ples. This analysis revealed two principal groups, com-
posed of BCLs and PCTs, as shown in Figures 1B and 1C.BMC Genomics 2007, 8:302 http://www.biomedcentral.com/1471-2164/8/302
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With few exceptions, most of the PCTs, regardless of trans-
genic differences or viral agents accelerating appearance of
PCTs, clustered together (blue-green dendrogram, Figures
1B and 1C). This cluster included both forms of PCTs that
arose in IL-6-transgenic BALB/c mice: KiPCs, which arose
intraperitoneally after ip pristane, and IL6PCs, which
spontaneously arose in hyperplastic lymph nodes, inde-
pendent of ip pristane. These results indicated that all
PCTs share a common genetic expression signature. The
IL-6-pre-malignant transgenic lymph node samples
(IL6LN) did not cluster with the IL6PCs. Instead, these
clustered with the BCLs (red-orange dendrogram, Figures
1B and 1C). ABLS are pre-B cell lymphomas induced by
Abelson virus infection. Note that while the v-Abl-con-
taining retroviruses also produced two subtypes of PCTs
(ABPCs and ABLMYCPCs), the ABLSs clustered with
BCLEµ and BCLCα, suggesting that cell type influenced
gene expression more than v-Abl, in this situation.
The nature of c-Myc-activating chromosomal transloca-
tions, i.e., typical T(12;15) vs. variant T(6;15) [11,12], did
not affect their inclusion in the PCT group, nor did it lead
to subclusters within the ABPC or TEPC subgroups in this
particular analysis (Figure 1B and 1C). Instead, tumor
sample subclustering was influenced more by the agents
used to accelerate PCT development, generating subclus-
ters within the PCT cluster, each of which contained virtu-
ally only one PCT subclass, ABLMYCPC, ABPC, IL6PC,
KiPC or TEPC. Note that ABPCs and ABLMYCPCs clus-
tered with each other before clustering with other PCTs,
indicating a greater degree of similarity between these two
groups of PCTs, both of which were accelerated by v-Abl.
The two forms of PCTs that arose in IL-6-transgenic BALB/
c mice also clustered most closely with one another.
Constitutive expression of IL-6 in IL-6-transgenic mice
triggers polyclonal plasmacytosis in lymphoid organs
such as lymph nodes and spleen [14], and neoplastic
transformation of these plasma cells occurs spontane-
ously over time [13]. Thus, RNA samples from 6 enlarged
lymph nodes in young IL-6-transgenic BALB/c mice were
provisionally designated IL6LN (rich in pre-malignant
cells), while samples from 8 larger lymph nodes from
older mice were designated IL6PC (now containing trans-
formed plasma cells). As expected, hierarchical clustering
grouped all 8 IL6PCs into the "Plasma Cell Tumor" clus-
ter. However, two of the "IL6LN" samples, expected to be
pre-malignant, owing to the younger ages of these trans-
genic mice, clustered with the IL6PC samples in the PCT
group and are marked with asterisks in Figure 1B. Since
the remaining four samples of IL6LN were tightly clus-
tered with the bulk of the B-cell lymphomas in the BCL
group, we took this finding as evidence that the two PCT-
like IL6LN samples probably contained a significant per-
centage of transformed plasma cells.
Class comparison of the two main clusters revealed major,
consistent gene expression differences between PCTs and
BCLs. To gain biological insight into these differences, a
two-sample t-test was applied to select the genes whose
expression was significantly different between these two
groups (926 genes, p < 1 × 10-5). Functional enrichment
analysis [see Additional file 1] based on gene ontology
(GO) terms showed that these expression differences were
heavily enriched for B cell-specific genes that were gener-
ally downregulated in plasma cells [15-17]. Figure 2
presents heat maps of a subset of those genes from catego-
ries of gene functions assigned by Cancer Genome Anat-
omy Project (CGAP), illustrating that that PCTs and BCLs
mobilize different signal transduction pathways. It is
interesting to note that the majority of the gene differ-
ences consist of downregulation of genes in PCTs. It is
likely that this reflects the wholesale focusing of the pro-
Table 1: Summary of mouse tumors studied by Affymetrix microarray profiling
Tumors Cited as Exogenous gene 
effect
Tumor type Site of origin N
PCT-1 ABLMYCPC v-Abl + c-Myc Virus-accelerated ip 
PCT
intraperitoneal 7
PCT-2 ABPC v-Abl Virus-accelerated ip 
PCT
intraperitoneal 12
PCT-3 J3PC v-Raf + v-Myc Virus-accelerated ip 
PCT
intraperitoneal 4
PCT-4 KiPC IL-6 transgene Transgene-accelerated 
ip PCT
intraperitoneal 3
PCT-5 IL6PC IL-6 transgene Spontaneous PCT gut-associated 
lymphoid tissue
8
PCT-6 TEPC, LPC, MOPC none Pristane oil-induced ip 
PCT
intraperitoneal 18
BCL-1 IL6LN IL-6 transgene Spontaneous pre-
malignant PCT
gut-associated 
lymphoid tissue
6
BCL-2 Pre B v-Abl (a.k.a. 
ABLS)
v-Abl Virus-accelerated Pre-B 
lymphoma
bone marrow + spleen 6
BCL-3 BCLEm c-Myc in Igm locus Spontaneous BCL lymph nodes 3
BCL-4 BCLCa c-Myc in Iga locus Spontaneous BCL lymph nodes 3BMC Genomics 2007, 8:302 http://www.biomedcentral.com/1471-2164/8/302
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Gene expression analysis of mouse plasmacytomas and B cell lymphomas Figure 1
Gene expression analysis of mouse plasmacytomas and B cell lymphomas. 70 RNA samples from murine B-cell 
malignancies, comprised of 6 different types of mouse plasma cell tumors and 4 different types of mouse B cell lymphomas, 
were used for global gene expression studies. A. Kinetics of appearance of 6 different subclasses of plasma cell 
tumors. Time course of appearance of PCTs after ip injection of pristane. IL6PCs arose spontaneously in lymph nodes of IL-6-
transgenic mice, without pristane treatment, as the mice aged. See Table 1 for more details. B and C. Unsupervised hierar-
chical clustering. Using Affymetrix U74A v2 microarrays, 6424 genes were used for clustering of genes and samples after fil-
tering out genes with more than 50% of A (absence) calls. Correlation-based (uncentered) average linkage clustering was 
performed on log base 2-transformed data previously centered to mean expression values of each gene. Gene expressions 
above this mean value are colored red; those expressed below are shown in green. The cluster dendrogram shows 2 major 
sample clusters: a PCT cluster and a B-cell lymphoma cluster. Samples are coded with 11 different colors based on previously 
assigned groups. Asterisks indicate samples that clustered in an unexpected manner (see text). In the dendrogram, the PCT 
samples are colored blue-green and the BCL samples are red-orange. In the first color bar, different viral and transgenic contri-
butions to PCT development are distinguished by different colors. In the second color bar, the 4 types of BCLs are color-
coded. In the third color bar, mouse PCTs previously characterized for the fine structure of their Myc-activating chromosomal 
translocations are identified in this dendrogram. PCT samples having the variant chromosomal translocation T(6;15) are shown 
in deep blue, type I T(12;15) are shown in red/orange, and type II T(12;15) are shown in light blue. PCT samples having com-
plex chromosomal translocations [12] are shown in purple, and PCT samples having no identifiable chromosomal transloca-
tions are shown in pale black. Boxes without color indicate PCTs with unknown karyotypes.BMC Genomics 2007, 8:302 http://www.biomedcentral.com/1471-2164/8/302
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Genes showing significant differences in expression between PCTs and BCLs Figure 2
Genes showing significant differences in expression between PCTs and BCLs. Class comparison between PCTs and 
BCLs showed 926 genes that showed significant differences (p < 1 × 10-5) in two sample t-test. The genes assigned to 8 differ-
ent functional categories by CGAP are presented as a heat map of gene cluster. Additional details can be found in Additional 
file 1.BMC Genomics 2007, 8:302 http://www.biomedcentral.com/1471-2164/8/302
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tein synthesis machinery of these antibody-secreting "fac-
tories" on the production of their characteristic protein.
The genes with higher expression in PCTs include Cyclin
D2 (Ccnd2), syndecan1 (Sdc1), Irf4, and Xbp1. Irf4 and
syndecan1 (CD138) were previously reported to have
increased expression in plasma cells [15,16,18-20]. Cyclin
D2 was previously reported to be induced by c-Myc activa-
tion [21]. Several pro-collagens (Col1a1, Col1a2, Col3a1,
and Col5a1) also showed higher expression in PCTs than
in BCLs. As expected, transcription factors previously
known to have higher expression in plasma cells, Xbp1,
Cebpb, and Irf4 [15,16] also showed higher expression in
PCT groups.
B-cell surface markers (e.g., CD79b, CD19, and CD22)
were highly expressed in BCL samples, as expected.
Expression of caspases (e.g., Casp3, Casp6 and Casp7)
was higher in the BCL group, as was expression of the
chemokines (Ccr7), cytokines (IL-16, IL18) and cytokine
receptors (IL1r2, IL3ra, IL7r, and IL10ra). An additional
relevant gene that was more highly expressed in the BCL
group was Syk, a tyrosine kinase that is essential for B-cell
antigen receptor triggering of cellular activation [22].
Genes involved in Jak-Stat signaling (Jak1, Stat4) and
NFκB signaling (NFκB1) also showed higher expression
in the BCL groups. None of these functions are thought to
be active after B cells differentiate into plasma cells, which
have lost nearly all their surface receptors and downregu-
lated many other B-cell-specific genes. Although whole
lymph nodes were used as samples in IL-6-transgenic
PCTs and LN, the lower expression of B-cell surface mark-
ers seen in the expression profiles of the IL6PCs suggests
that the main populations of cells in IL-6-transgenic
mouse lymph nodes are plasma cells, which typically lose
expression of most surface markers. Our results confirm
the histological finding that percentage of B- and T lym-
phocytes decreased as the lymph nodes fill with plasma
cells and PCTs [14].
Genes reflecting v-Abl-accelerated PCT induction
A direct comparison between two groups of PCTs: the
rapid onset PCTs (ABPC and ABLMYC) and the slow onset
PCTs, (TEPC, KiPC and IL6PC) was performed to get
information on genes that might have contributed to the
acceleration. A two-sample t-test between these two
groups revealed 1195 genes with significant (p < 0.001)
expression differences. Among these 1195 genes, 80 genes
showed greater than 2-fold higher expression in the ABPC
plus ABLMYC group, while 83 genes showed greater than
2-fold higher expression in the TEPC, KiPC and IL6PC
group [see Additional file 2]. Several genes involved in cel-
lular growth and proliferation (Cdkn2b, Tgfb1, Ptprc,
Cd6, Gfi1, and Mybl2) showed higher expression in the
ABPC plus ABLMYC group, as did many interferon-
induced genes, presumably induced by the presence of
retroviruses in this group. Several genes involved in cell
death (Ada, Bid1, Gas6, Prkcζ,) were higher in TEPCs,
KiPCs and IL6PCs. Table 2 lists a subset of these genes
arranged by their categories of gene functions assigned by
CGAP.
Effects of v-Abl
The gene expression levels of Socs1 and Socs2 (Suppressors
of Cell Signaling 1 and 2) showed very high levels in all
Abelson virus-infected samples (ABPC, ABLMYCPC) com-
pared to other PCTs [see Additional file 2]. Socs 1 & 2 are
proteins that normally interrupt Jak/Stat signaling [23],
but their growth-inhibiting effects are abrogated by the v-
Abl protein [24,25]. These high levels of Socs expression
are likely to reflect the continuous activation of Jak-STAT
expected from v-Abl [26]. This hyperactive Jak/STAT path-
way may be partly responsible for the rapid appearance of
ABPCs and ABLMYCPCs compared to TEPCs, as shown in
Figure 1A.
Sensitivity of v-Abl accelerated PCTs to treatment with 
STI-571
The main difference between ABPCs and TEPCs is the
acceleration of plasma cell tumor formation by the v-Abl
gene. The high levels of Socs1 &2 expression in ABPCs sug-
gested that v-Abl was active in the fully mature PCTs. To
confirm this finding and to determine whether fully trans-
formed PCTs still retained a requirement for the v-Abl
kinase that accelerated its appearance, cell survival analy-
sis was performed after treatment of tissue culture lines of
ABPC 20, ABPC 22, TEPC 1165, TEPC 2027 and pre B v-
Abl lymphoma with 0.1 to 2.0 µM STI-571, an Abl kinase
inhibitor [27]. Figure 3A shows a clear difference in the
susceptibility of those cell lines to STI-571. ABPCs
(ABPC20, ABPC22) and pre B cell lymphoma (pre B v-
Abl) generated by Abelson virus infection showed higher
susceptibility to STI-571 with complete inhibition of cell
growth at 0.1 µM of STI-571 solution, while TEPC 1165
and TEPC 2027 showed no inhibition of cell growth even
at 2 µM STI-571. Those data suggest that v-Abl  is still
required for cell survival and proliferation even in fully
transformed ABPCs as was previously shown for v-Abl-
induced pre B lymphomas [28].
STI-571 inhibits Stat activation of v-Abl accelerated PCT 
and pre B lymphoma
The preceding analysis suggests that the v-Abl-induced
PCTs utilize the Jak/STAT signaling pathways. As shown in
Figure 3B, the PCT cell lines studied showed highly acti-
vated (phosphorylated) STAT1 and STAT3. However treat-
ment with 5 mM STI-571 led to decreased
phosphorylation of STAT1 and STAT3, but only in the cell
lines induced with Abelson virus, ABPC 20 cell line and
pre B v-Abl lymphoma. This dose of STI-571 had no effectBMC Genomics 2007, 8:302 http://www.biomedcentral.com/1471-2164/8/302
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Table 2: Genes showing significant differences in expression between rapid-forming PCTs (ABPC and ABLMYCPC) and slow-forming 
PCTs (TEPC, IL6PC and KiPC)
Higher in slow-forming PCT (TEPC, IL6PC, KiPC
Gene 
function
Rapid 
PCT
Slow PCT Fold 
difference 
(slow/rapid)
Description Unigene ID Gene 
symbol
p-value
Angiogenesis
308.4 495.6 1.6 Neogenin Mm.42249 Neo1 1.05E-05
Apoptosis
2872.8 5249.1 1.8 RIKEN cDNA A630035D09 gene Mm.238213 Bcl2l1 4.67E-05
Cell cycle
583.6 2799.1 4.8 Megakaryocyte-associated tyrosine kinase Mm.2918 Matk < 1E-07
270.1 912.6 3.4 Protein kinase C, zeta Mm.28561 Prkcz < 1E-07
208.1 364.3 1.8 Acid phosphatase, prostate Mm.19941 Acpp 2.10E-06
280.7 473.5 1.7 Cyclin D1 Mm.273049 Ccnd1 7.12E-05
1484.3 2441.1 1.6 Casein kinase 1, epsilon Mm.30199 Csnk1e 3.50E-06
Immune response
204.1 535.4 2.6 Prolactin receptor Mm.10516 Prlr 5.4E-06
124 267.7 2.2 Transforming growth factor, beta receptor III Mm.200775 Tgfbr3 1.2E-06
2872.8 5249.1 1.8 RIKEN cDNA A630035D09 gene Mm.238213 Bcl2l1 4.67E-05
707.2 1243.1 1.8 AU RNA binding protein/enoyl-coenzyme A hydratase Mm.252034 Auh 3.2E-06
1000.1 1751.7 1.8 Aldehyde dehydrogenase 2, mitochondrial Mm.284446 Aldh2 3.56E-05
2990.5 5228.6 1.7 Glucosidase, beta, acid Mm.5031 Gba < 1E-07
942.5 1629.7 1.7 AU RNA binding protein/enoyl-coenzyme A hydratase Mm.252034 Auh < 1E-07
7349 12562.5 1.7 CCAAT/enhancer binding protein (C/EBP), beta Mm.347406 Cebpb 1E-07
752.1 1285.1 1.7 Profilin 1 Mm.2647 Pfn1 3.5E-06
912.2 1538.3 1.7 Aldehyde dehydrogenase 2, mitochondrial Mm.284446 Aldh2 6.2E-05
2311.2 3862.5 1.7 Epidermal growth factor receptor pathway substrate 15 Mm.318250 Eps15 1.24E-05
166.2 274.5 1.7 Microphthalmia-associated transcription factor Mm.333284 Mitf 7.9E-06
722.3 1097.6 1.5 Amyloid beta (A4) precursor protein-binding, family B, 
member 1
Mm.38469 Apbb1 7E-06
749.6 1135 1.5 Glutathione synthetase Mm.252316 Gss 7.61E-05
Transcription factor
294 803.5 2.7 AT motif binding factor 1 Mm.196564 Atbf1 < 1e-07
247.9 639.4 2.6 E74-like factor 3 Mm.3963 Elf3 6.80E-06
844.6 1883 2.2 Pre B-cell leukemia transcription factor 1 Mm.43358 Pbx1 < 1E-07
765.9 1554.6 2.0 POU domain, class 2, transcription factor 2 Mm.208700 Pou2f2 2.30E-06
7349 12562.5 1.7 CCAAT/enhancer binding protein (C/EBP), beta Mm.347406 Cebpb 1.00E-07
162.2 252.2 1.6 RIKEN cDNA 2310011G17 gene Mm.254233 2310011G1
7 Rik
6.55E-05
Signal transduction
583.6 2799.1 4.8 Megakaryocyte-associated tyrosine kinase Mm.2918 Matk < 1E-07
270.1 912.6 3.4 Protein kinase C, zeta Mm.28561 Prkcz < 1E-07
1484.3 2441.1 1.6 Casein kinase 1, epsilon Mm.30199 Csnk1e 3.50E-06
456.5 729.4 1.6 Homeodomain interacting protein kinase 3 Mm.257925 Hipk3 2.11E-05
Development
844.6 1883 2.2 Pre B-cell leukemia transcription factor 1 Mm.43358 Pbx1 < 1E-07
Higher in rapid-forming PCT (ABPC and ABLMYCPC)
Gene 
function
Rapid 
PCT
Slow PCT Fold 
difference 
(rapid/slow)
Description Unigene ID Gene 
symbol
p-valueBMC Genomics 2007, 8:302 http://www.biomedcentral.com/1471-2164/8/302
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Angiogenesis
1868.3 902.8 2.1 Plasminogen activator, urokinase Mm.4183 Plau 8.29E-05
9821.9 4360.2 2.3 CD53 antigen Mm.316861 Cd53 3.40E-06
Apoptosis
2588.3 1681.2 1.5 BCL2-antagonist/killer 1 Mm.2443 Bak1 9.11E-05
Cell cycle
2231.6 1126.6 2.0 Proliferation-associated 2G4 Mm.4742 Pa2g4 2.76E-05
4858.7 2552.3 1.9 Adenylate kinase 2 Mm.29460 Ak2 < 1E-07
10477 6082.1 1.7 CDC28 protein kinase regulatory subunit 2 Mm.222228 Cks2 < 1E-07
1371.5 869.3 1.6 Casein kinase II, alpha 2, polypeptide Mm.51136 Csnk2a2 1.90E-06
Immune response
3568.1 386 9.2 CD6 antigen Mm.290897 Cd6 2.00E-07
984.7 186.1 5.3 Tubulin, alpha 3 Mm.287784 Tuba3 < 1E-07
2661.9 718.2 3.7 BH3 interacting domain death agonist Mm.235081 Bid < 1E-07
7492.6 2554.5 2.9 Acetyl-Coenzyme A dehydrogenase, medium chain Mm.10530 Acadm < 1E-07
3195.6 1346.2 2.4 Inositol (myo)-1(or 4)-monophosphatase 1 Mm.183042 Impa1 < 1E-07
2455 1064.3 2.3 RAS-related protein-1a Mm.333868 Rap1a < 1E-07
9821.9 4360.2 2.3 CD53 antigen Mm.316861 Cd53 3.40E-06
7479.7 3365.9 2.2 Transporter 1, ATP-binding cassette, sub-family B (MDR/
TAP)
Mm.207996 Tap1 < 1E-07
7347.8 3535.9 2.1 Superoxide dismutase 1, soluble Mm.276325 Sod1 < 1E-07
365.9 179.9 2.0 Growth factor independent 1 Mm.2078 Gfi1 1.30E-05
2231.6 1126.6 2.0 Proliferation-associated 2G4 Mm.4742 Pa2g4 2.76E-05
1939.9 985.5 2.0 RAS-related protein-1a Mm.333868 Rap1a 4.00E-07
450.3 261.9 1.7 Ets variant gene 4 (E1A enhancer binding protein, E1AF) Mm.5025 Etv4 1.40E-06
3031.7 1830.6 1.7 Wiskott-Aldrich syndrome homolog (human) Mm.4735 Was 5.13E-06
3136.7 1944.6 1.6 Chromosome segregation 1-like (S. cerevisiae) Mm.22417 Cse1l 2.67E-05
5738.7 3586.7 1.6 Survival motor neuron 1 Mm.2025 Smn1 2.75E-05
395.2 252.8 1.6 Dihydrofolate reductase Mm.23695 Dhfr 2.70E-06
2017.5 1297.8 1.6 FK506 binding protein 12-rapamycin associated protein 1 Mm.21158 Frap1 8.46E-05
2588.3 1681.2 1.5 BCL2-antagonist/killer 1 Mm.2443 Bak1 9.11E-05
4410.1 2873.4 1.5 Ribonucleotide reductase M1 Mm.197486 Rrm1 5.14E-05
5971.6 3940.2 1.5 Integrin beta 4 binding protein Mm.271674 Itgb4bp 6.94E-05
18860.1 12494.5 1.5 Triosephosphate isomerase 1 Mm.4222 Tpi1 8.30E-06
Transcription factor
6231.6 1885.8 3.3 Lymphoblastomic leukemia Mm.4925 Lyl1 < 1E-07
3274.2 1544.3 2.1 Chromodomain helicase DNA binding protein 1 Mm.8137 Chd1 < 1E-07
450.3 261.9 1.7 Ets variant gene 4 (E1A enhancer binding protein, E1AF) Mm.5025 Etv4 1.40E-06
3136.7 1944.6 1.6 Chromosome segregation 1-like (S. cerevisiae) Mm.22417 Cse1l 2.67E-05
Signal transduction
4858.7 2552.3 1.9 Adenylate kinase 2 Mm.29460 Ak2 < 1E-07
10477 6082.1 1.7 CDC28 protein kinase regulatory subunit 2 Mm.222228 Cks2 < 1E-07
3031.7 1830.6 1.7 Wiskott-Aldrich syndrome homolog (human) Mm.4735 Was 5.13E-05
1371.5 869.3 1.6 Casein kinase II, alpha 2, polypeptide Mm.51136 Csnk2a2 1.90E-06
DNA replication
3805.2 2420.4 1.6 Small nuclear ribonucleoprotein polypeptide A' Mm.821 Snrpa1 < 1e-07
8247.5 4325.9 1.9 Replication protein A1 Mm.180734 Rpa1 4.20E-06
Class comparison between slow-forming PCTs (TEPC, IL6PC and KiPC) and rapid-forming PCTs (ABPC and ABLMYCPC) by two-sample t-test generated 1195 genes 
showing significant differences (p- value < 0.001). Among these 1195 genes, the genes showing more than 1.5 fold increase and p-value < 0.0001 were selected in this table. 
The genes in each category of gene function were assigned based on the annotation of CGAP.
Table 2: Genes showing significant differences in expression between rapid-forming PCTs (ABPC and ABLMYCPC) and slow-forming 
PCTs (TEPC, IL6PC and KiPC) (Continued)BMC Genomics 2007, 8:302 http://www.biomedcentral.com/1471-2164/8/302
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on phosphorylation of STAT1 or STAT3 in TEPC 1165 and
TEPC 2027. Presumably the latter PCTs also utilized the
Jak/Stat signaling pathways, but they were not stimulated
by Abl. What is more, 5 µM STI-571 completely inhibited
the STAT1 phosphorylation in ABPC 20 and pre B v-Abl
lymphoma and the STAT3 tyrosine phosphorylation in
pre B v-Abl, and it virtually completely inhibited the tyro-
sine and serine phosphorylation of STAT3 in ABPC 20.
Signals activating STAT3 can also come from other differ-
ent pathways (e.g., those responsible for STAT phosphor-
ylation in TEPC 1165 and TEPC 2027, such as Ras
activation by c-Myc). In contrast, STAT3 activation of the
Greater sensitivity of ABPCs to STI-571 than TEPCs Figure 3
Greater sensitivity of ABPCs to STI-571 than TEPCs. A. Cell proliferation analysis of PCTs after treatment 
with STI-571. Five different cell lines including two ABPCs (ABPC20, ABPC22), two TEPCs (TEPC1165, TEPC 2027) and one 
pre B v-Abl lymphoma were treated with different concentrations of STI-571 at an initial concentration of 5 × 103 cells/well. 
Cell numbers were measured at 4 different times (0, 2, 4, and 7 days after treatment). B. Western blot analysis of PCTs 
for STAT1 phosphorylation and STAT3 phosphorylation. Samples for western blot were collected from untreated 
cells and cells after treatment with 5 µM STI-571 for 18 hours. Doublet bands are the α and β forms of the STAT proteins.BMC Genomics 2007, 8:302 http://www.biomedcentral.com/1471-2164/8/302
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pre B v-Abl line comes almost exclusively from v-Abl, as
was shown in v-Abl-transformed pre B-cells [24]. STI-
571's selective inhibition of Stat activation in ABPC 20
and pre B v-Abl lymphoma suggests that the v-Abl signal-
ing pathways are still critical for viability, even in fully
transformed tissue-cultured tumors.
Quantitative RT-PCR analysis
For validation of certain key findings in the microarray
data, real time RT-PCR was performed for 9 selected genes
that may play significant roles in PCTs (Figure 4). Thirteen
different tumor RNA samples (6 ABPC, 4 TEPC and 3
ABLS) were analyzed, using RNA from the sample that
showed the lowest expression as calibrator for each gene.
Means for each of the three tumor types are shown in Fig-
ure 4, and individual results are presented in Additional
file 3. These results paralleled the mRNA expression levels
acquired via microarray analysis. c-Myc  expression was
generally highest in the four TEPC samples, while it
showed lowest expression in the v-Abl-expressing ABLS
(pre-B cell lymphomas). Socs1 and Socs2 expression was
hi g h e r  i n  A BP C  a n d  A BL S  t h a n  i n T E P C  s a mp l e s .  T h e
genes previously known to be plasma cell-specific tran-
scription factors (Xbp1 and Irf4) and surface marker
(Sdc1/CD138) showed higher expression in PCTs than in
pre-B cell lymphomas (ABLS). Jak1 expression was higher
in the pre-B lymphomas than in the PCTs.
Differences of gene expressions based on c-Myc gene 
chromosomal translocations
Cluster analysis suggested that the site of chromosomal
translocation on chromosome 15 and the nature of its
translocation partner chromosome did not affect the gene
expression profile as much as additional oncogenes play
in PCT induction. To test this concept more stringently, a
two-sample t-test was used to search for differences in
gene expression between typical T(12;15) and variant
T(6;15) chromosomal translocations within a single sub-
group of PCTs, ABPCs. Only 14 genes, most of which had
low levels of expression, showed significant difference in
expression, suggesting that the site of translocation had
little effect on the mechanism of transformation of the
PCTs [see Additional file 4]. Another t-test was performed
to compare the effect of two different forms of T(12;15),
class I or II, in TEPCs [see Additional file 4]. This showed
29 genes with significant differences in expression, also
relatively low in expression, consistent with the previous
comparison and our interpretation that the different
forms of chromosomal translocation did not affect signif-
icant differences in mechanism of transformations or the
type of cell being transformed. This analysis cannot rule
out some differences in early neoplastic events, since we
were only examining expression values from fully trans-
formed tumors.
Meta-analysis of the mouse expression data co-mingled 
with expression pattern data for human plasma cell 
neoplasms
Having defined distinctive gene expression patterns
among the PCT subtypes as well as between PCTs and
BCLs, we next sought to examine how well our mouse
models recapitulate human phenotypes as measured by
relative similarities of gene expression patterns. Mouse
plasmacytomas form in the intraperitoneal cavity, while
human multiple myelomas are found in bone marrow,
very different locations but not without potentially mean-
ingful similarities: richness in adipocytes, plentiful reac-
tive myeloid cells, abundant blood supply, among others.
We used gene expression data from human B lymphocytes
and human multiple myeloma isolates, and cross-com-
pared them with the gene expression data from our mod-
els. Using genes that existed as orthologues in both
human and mouse Affymetrix chips, unsupervised cluster
analysis showed that BCLs (human and mouse) clustered
separately from the PCTs and MMs [see Additional file 5].
Since the B-cell components in this series were small in
number, we focused our analysis on the plasma cell com-
ponents, human and murine. The human multiple mye-
loma samples had been previously assigned to MM1-
MM4 subgroups, based on cluster analysis of gene expres-
sion patterns of bone-marrow plasma cells from patients
Quantitative real-time PCR analysis Figure 4
Quantitative real-time PCR analysis. qRT-PCR was per-
formed on RNAs from 3 different groups of cultured cells to 
analyze relative mRNA content for 9 key genes: c-Myc, Socs1, 
Socs 2, Abl1, Jak1, Xbp1, Sdc1, Irf4, Pax5 as well as the "house-
keeping gene", GAPDH, using primers and detection oligos 
designed in consultation with the manufacturer (ABI). The 
data was presented as mean ± standard deviation values of 
each group. qRT-PCR data for individual samples are pre-
sented as Additional file 3. All data were normalized to 
GAPDH. These values were then calibrated against the sam-
ple with the lowest expression and represented as -∆∆Ct 
values with standard errors.BMC Genomics 2007, 8:302 http://www.biomedcentral.com/1471-2164/8/302
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with multiple myeloma [18,19]. When PCTs and MMs
were re-analyzed without the B-cell components, there
was co-stratification of mouse and human tumors in such
a way that the more aggressive MM3 and MM4 co-clus-
tered with the accelerated PCT-1 and -2 (ABLMYCPCs and
ABPCs), while MM1 co-clustered with IL-6 transgenic
PCTs (KiPCs and IL6PCs) (Figure 5). The slow-arising
TEPCs (PCT-6) co-clustered with the less aggressive MM1-
MM2 patients. This intriguing inter-species co-clustering
of plasma cell neoplasms will be investigated in greater
depth in another study that will incorporate more recent
myeloma data [29] that present a new molecular classifi-
cation of myelomas into seven subgroups.
Discussion
Microarray expression profiling has been quite successful
in differentiating subclasses within tumors with a similar
histological/morphological diagnosis [18,30]. Tumors
with common genetic lesions tend to cluster together,
reflecting the fact that deregulation of one or more genes
leads to downstream gene activation/inactivation cas-
cades that are unique to that lesion. It has also made it
possible to predict the prognosis of cancer patients and
the likelihood of their responding to chemotherapy,
based on gene expression patterns [18,31]. Major progress
in experimental cancer research will require animal model
systems and in vitro cell culture systems. Experimentally
induced PCTs and related BCLs have long been, and con-
tinue to be, useful for the study of plasma cell neoplasms.
In this study, we generated gene expression profiles of
mouse B-lymphocytic neoplasms, including four groups
of PCTs that arose with different latent periods in chronic
inflammatory tissue induced by ip pristane. We also stud-
ied two subgroups of PCTs that arose spontaneously in
hyperplastic lymph nodes of IL-6-transgenic mice and B-
cell lymphomas from iMyc gene-insertion mice. Statistical
methods were employed to compare these expression pro-
files to search for specific gene expression signatures that
might aid in understanding the molecular mechanisms at
work in each subtype of B cell malignancy and the differ-
ences in tumor latent periods resulting from variation in
the PCT induction schemes.
Classical unsupervised clustering analysis and statistical
analysis of microarray data revealed a tight clustering of
PCTs regardless of subtype. The expression patterns in this
group showed major differences from those of the B-cell
lymphoma group. As seen in earlier analyses [30], the
stage of B cell differentiation strongly influenced the
major gene expression differences. It is important to note
that virtually all of the PCTs clustered together, including
both intraperitoneal oil-induced PCTs as well as those
that arose spontaneously in IL-6-transgenic lymph nodes,
independent of ip pristane. These results indicated that all
PCTs share a common genetic expression signature. It can
also be seen that many genes present in the B-cell signa-
ture have been downregulated in the PCT signature, a
well-known feature of the specialized plasma cell, which
seems to reflect this cell's single-minded dedication to
maximize synthesis of antibody Ig.
Many of the genes that emerged as part of the PCT signa-
ture after unsupervised clustering analysis had been recog-
nized in previous studies of gene expression patterns as
characteristic of this stage of B cell differentiation, before
and after neoplastic transformation [17,19,32]. Irf4 and
Syndecan1 are characteristically expressed in plasma cells,
and cyclin D2 has been reported to have high expression
in PCT, presumably secondary to deregulated c-Myc.
Subclusters within the PCT cluster were seen, chiefly
reflecting the slow vs. rapid appearance of the PCTs and
the nature of the accelerating oncogenes. Unlike human
myelomas, mouse plasma cell tumors have a common
initiating event, a Myc-activating chromosome transloca-
tion. We found that unsupervised clustering of these
tumors did not reveal major differences in gene expres-
sion that could be associated with position of breakpoint
and translocation on chromosome 15. That is, the nature
of c-Myc-activating chromosomal translocations [i.e., typ-
ical T(12;15) vs. variant T(6;15)] did not affect their inclu-
sion in the PCT group, nor did it lead to subclusters within
the broad PCT grouping or the ABPC or TEPC subgroups,
in this particular analysis. This supports our hypothesis
that even T(6;15) translocations that occur within the Pvt-
1 region initiate PCTs via induction of constitutive c-Myc
expression, and that fine structural differences in the site
of T(12;15) within or near the c-Myc locus itself do not
materially affect the way Myc influences PCT induction.
Of course, we know that additional genetic events are
required for complete transformation of plasma cells, for
Myc-activating chromosome translocations have been
found in normal cells and organs that did not develop
plasma cell tumors [33]. Future studies will focus on iden-
tifying these additional events that occur during tumor
progression.
Our cluster analysis did, however, reflect differences in the
cooperating genes used to accelerate tumorigenesis. The
most striking gene expression changes associated with
tumors accelerated by Abelson virus infection are the high
levels of Socs1 expression. The Socs proteins are inhibitors
of signaling pathways and are generally expressed at low
levels in unstimulated cells. They become rapidly induced
by cytokines, thereby inhibiting Jak-STAT signaling, form-
ing a classic negative feedback loop [34]. It was previously
shown that the v-Abl oncogene activates Jak-STAT signal-
ing during transformation of pre-B cells in mice [24].
Although Socs-1 is highly expressed in v-Abl-transformedBMC Genomics 2007, 8:302 http://www.biomedcentral.com/1471-2164/8/302
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Meta-analysis of human multiple myeloma samples with mouse plasmacytomas Figure 5
Meta-analysis of human multiple myeloma samples with mouse plasmacytomas. A total of 122 samples, comprised 
of 74 human samples and 48 mouse samples, were used for this meta-analysis. Human samples had previously classified into 4 
different stages of multiple myeloma (MM1, MM2, MM3 and MM4, generally reflecting increasing severity or stage of disease 
[18]), and mouse samples were composed of 5 different PCT groups, ABPC and ABLMYCPC, "two accelerated subgroups 
[PCT-1 and -2] (Table 1)", and "TEPC, KiPC and IL6PC, the slower appearing subgroups [PCTs 4 – 6] (Table 1)". The stage of 
myeloma and group of plasma cell tumors to which each sample belongs is indicated by the color of the rows of boxes beneath 
sample names, with a color key beneath the heat map. The human and mouse data were normalized and standardized sepa-
rately and then combined for analysis [40,41]. The genes for cluster analysis were selected by one-way ANOVA analysis (2266 
genes, p-value < 0.001) of mouse PCTs, and 634 orthologs from these 2266 genes, present both in human and mouse array 
platforms were used for cluster analysis.BMC Genomics 2007, 8:302 http://www.biomedcentral.com/1471-2164/8/302
Page 13 of 16
(page number not for citation purposes)
cells, it is unable to inhibit v-Abl-mediated Jak- STAT sign-
aling. This is thought to be the result of one of the non-
tyrosine kinase effects of v-Abl, such as phosphorylation
of Socs-1 on non-tyrosine residues, leading to disruption
of the interaction between Socs-1 and the elongin B/C
complex and inhibition of Socs1-mediated proteasome
targeting of activated Jaks [24]. STI-571/Imatinib
(Gleevec, Novartis Pharma), at low concentrations, is a
specific inhibitor of Abl kinase and shows effectiveness in
the treatment of chronic myelogenous leukemia [27,35].
ABPC20, ABPC22 and pre B v-Abl are much more sensi-
tive to killing by STI-571 than TEPC1165 or TEPC2027
(Figure 3A), indicating that the Abl kinase activity is still
required for viability of PCTs induced with the assistance
of Abelson Virus. Since nearly all ABPCs also show c-Myc-
activating chromosome translocations, some cooperation
between the signaling pathways of v-Abl and c-Myc must
be responsible for the rapid transformation of ABPCs.
Unexpectedly, however, this cooperation appears to be
required even after full transformation is achieved and
even after adaptation to growth in culture. It will be inter-
esting to see if resistance to STI-571 develops in these cul-
tures, as is often seen in human CML [31].
Stat4 is more highly expressed in the BCL group than in
PCTs. However, the level of stat3 expression does not dif-
fer significantly between BCLs and PCTs, both groups
showing relatively high expression levels. Jak1  also
showed higher expression in the BCL group compared to
PCTs, but Jak1 is relatively highly expressed, even in PCTs.
The accelerating mechanisms engaged after v-Abl infection
seems to utilize these pathways (Figure 3B), despite the
concomitant induction of the counteracting Socs family of
genes. These pathways are currently being studied in
greater depth at the translational and post-translational
levels within the PCT system, following up the leads
afforded by our gene expression studies and the initial
phosphorylation studies shown here, with the goals of
understanding the mechanisms at work.
It has been illuminating to analyze our mouse expression
data in conjunction with already published Affymetrix
data from human multiple myeloma. Cluster analysis
showed that human MM1 clustered most closely with
PCT4 and PCT5, IL6PC and KiPC, the two groups of PCTs
from IL-6-transgenic mice, while the more aggressive mye-
loma groups, MM3-MM4, clustered more tightly with
PCT1 and PCT2, ABLMYCPC and ABPC, those with
appearance accelerated by v-Abl activity. This similarity
includes differences in expression of genes associated with
proliferation. This was unexpected but significant,
because plasma cell neoplasms are not generally associ-
ated with rapid proliferation. Instead, increased survival
or escape from apoptosis is thought to be the chief mech-
anism responsible for the expansion of lymphocytes or
plasma cells in lymph nodes or bone marrow, respec-
tively. This similarity brings to mind the possibility that
Imatinib, the activated Abl inhibitor, might be effective in
treating aggressive myeloma patients.
This co-clustering suggests that different pathways can be
utilized to achieve a similar outcome, namely transforma-
tion of plasma cells. Thus, the mouse PCT model, despite
its biological differences from MM, offers an experimental
model for studying the details of the etiology of plasma
cell neoplasms with different degrees of aggressiveness,
much as seen in human myelomas. This aspect of our
study will be broadened to include new data on addi-
tional myeloma patients [29] in which expression data are
used to define seven subgroups that differ in their molec-
ular characteristics. This study will be the subject of a sep-
arate manuscript.
Conclusion
Lymphoid transformation and plasma cell tumor forma-
tion are complicated, multi-stage processes, so it is neces-
sary to study these processes prospectively using research
tools covering genome-wide changes in expression. The
present study shows that gene expression profiling can
differentiate B-cell lymphomas from plasma cell tumors
and also distinguish slow from accelerated plasma cell
tumors. These results and data obtained from the sensitiv-
ity of v-Abl-accelerated plasma cell tumors and their phos-
phorylated STAT proteins to the effects of STI-571 indicate
that these otherwise similar tumors utilize different sign-
aling pathways but share a common initiating genetic
lesion, a c-Myc-activating chromosome translocation. This
study of gene expression profiles of mouse B-cell lympho-
mas and several subclasses of plasma cell tumors provides
data that offer clues for the understanding of B-cell neo-
plasia and plasma cell tumor formation and the interpre-
tation of the prospective plasma cell tumor induction
studies that are now under way.
Methods
Sample selection and RNA preparation
A total of 70 samples of RNA were prepared from trans-
planted mouse tissues. All solid PCT samples (except
IL6PC) used for microarray hybridization had been trans-
planted at least once from the initial ip tumor tissue that
arose following pristane injection. As summarized in
Table 1, the four groups of BCLs and the six different PCT
subtypes originated as follows. TEPCs (PCT-6) were
obtained after ip injections of pristane in BALB/c mice [1].
ABPCs (PCT-2) and J3PCs (PCT-3) were obtained more
rapidly (Figure 1A) by introducing Abelson virus [2] or
J3V1 virus [3], retroviruses containing v-Abl, or v-Raf-1
and v-Myc genes, respectively, following the injection of
pristane in BALB/c mice. ABLMYCPCs (PCT-1) originated
even more rapidly in the pristane-conditioned perito-BMC Genomics 2007, 8:302 http://www.biomedcentral.com/1471-2164/8/302
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neum of BALB/c mice infected with ABLMYC virus [5], a
retrovirus that expresses both v-Abl  and c-Myc  genes.
IL6PCs (PCT-5) were obtained from hyperplastic lymph
nodes that spontaneously developed in IL-6-transgenic
BALB/c mice [8]. KiPCs (PCT-4) were generated by inject-
ing pristane intraperitoneally into IL-6-transgenic BALB/c
mice [7]. "Pre-malignant" IL6LN (BCL-1) were hyperplas-
tic lymph nodes of IL-6-transgenic BALB/c mice [13].
ABLS (a.k.a. preB vAbl and BCL-2) were pre-B lymphomas
that arose rapidly in lymphoid organs of Abelson virus-
treated BALB/c mice [2]. BCLEµ (BCLs-3) are lymphoblas-
tic B-cell lymphomas with a Burkitt-like morphology from
lymph nodes of transgenic iMycEm mice [9]. BCLCα (BCL-
4) were obtained from spleens of transgenic iMycCα mice
[10]. All mice were maintained in our conventional col-
ony on the NIH campus under Animal Study Protocol LG-
028. Total RNA was prepared by grinding pieces of
excised, snap frozen and otherwise unprocessed tissues in
liquid nitrogen and extraction in TRIzol (Invitrogen,
Carlsbad, CA) followed by further purification on RNAe-
asy columns (Qiagen, Inc., Valencia, CA).
Microarray hybridization
Affymetrix Murine Genome Set U74Av2 microarrays
(Affymetrix Inc., West Sacramento, CA) were used for the
hybridization of biotin-labeled cDNA probes synthesized
from 5 µg of total RNA or 1 µg poly(A)+ RNA using a
Superscript double-strand cDNA synthesis kit (Invitrogen,
Carlsbad, CA), Bioarray High Efficiency RNA transcript
labeling kit and Mg-catalyzed fragmentation kit (Enzo
Biochemicals Inc., Farmingdale, NY) according to the
manufacturers' instructions. Microarrays were stained
with phycoerythrin-streptavidin (Molecular Probes,
Carlsbad, CA), scanned with an Affymetrix GeneChip
scanner and analyzed with Affymetrix Microarray Analysis
Suite (MAS) version 5.0.
Statistical analysis of microarray data
BRB ArrayTools Version 3.0 [36] was used for the analysis
of the MAS 5.0 data set. A log base 2 transformation was
applied to the data set before arrays were normalized.
Each array was normalized using median values of gene
expression over the entire array (global normalization). A
median array was selected as the reference array for nor-
malization. Class comparison analysis was performed
with the two-sample t-test of BRB ArrayTools with the esti-
mation of false discovery rate. Cluster analysis was per-
formed with Cluster and Treeview [37]. For the cluster
analysis, the log base 2 transformed data were centered to
the mean values of each gene's expression. Significantly
enriched components defined in Gene Ontology (GO)
were determined based on hypergeometric distribution
analysis [38].
Meta-analysis of published data
The human multiple myeloma data and their classifica-
tion into subclasses MM1 – MM4 was previously reported
by Zhan et al. [18,19] using Affymetrix HuGeneFL
Genome Array chips (Affymetrix, Inc., West Sacramento,
CA). 3739 orthologues between the human FL microarray
and the mouse U74Av2 microarray were identified based
on curated Hu6800 orthology from Affymetrix [39]. Each
data set was normalized separately and then combined
together as reported earlier [40]. Before integrating the
human data set with the mouse data set, the expression of
each gene was standardized to a mean ± s.d. of 0 ± 1, inde-
pendently in both data sets as described [41].
Cell culture, proliferation assay and inhibition by STI-571
This laboratory has adapted a number of PCTs, including
TEPC 1165, TEPC 2027, ABPC22 and ABPC 20 studied
here, to in vitro growth in RPMI 1640 plus 10% fetal
bovine serum, 10 ng/ml IL-6, penicillin and streptomycin.
Inhibition of proliferation by STI-571/Imatinib/Gleevec
(Novartis, Basel, Switzerland) [27,35] was determined
using several different concentrations of inhibitor (from
0.1 µM to 2 µM) on an initial cell suspension of 5 × 103
cells/well of a 24-well plate. Cell proliferation was deter-
mined by counting the cells at 2 days, 4 days and 7 days
after treatment with STI-571.
Western blotting
Tissue cultured mouse PCT cells, with and without 5 µM
STI-571, were harvested after 18 hours of treatment and
were subjected to western blot analysis. Membranes were
probed with the following antibodies: STAT1, STAT3,
tyrosine 701-phosphorylated STAT1, tyrosine 705-phos-
phorylated STAT3 and serine 727-phosphorylated STAT3
(Cell Signaling, Beverly, MA).
Quantitative real-time PCR
Quantitative RT-PCR was performed using the ABI 7500
real time PCR system following the manufacturer's proto-
col. Mouse GAPDH primer and probes were used as the
normalization control in quantitative analysis. The prim-
ers and probes used in this study were purchased from
Applied Biosystems (Foster City, CA), and primer
sequences are available upon request. The relative mRNA
expression levels are expressed as -∆∆Ct, in which ∆Ct is
the difference between the threshold PCR cycle (Ct) value
of each experimental mRNA and that of the correspond-
ing internal control, GAPDH. The -∆∆Ct value is the dif-
ference between the ∆Ct value of each tissue and that of
the lowest-expressing sample, used as calibrator for that
gene [42].
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lists of genes that showed significant (p < 0.005) differences in expression 
between plasma cell tumors and B-cell lymphomas characterized by their 
functional enrichment according to biological processes defined by the 
Gene Ontology Consortium. The enrichment of gene set was estimated by 
calculating the cumulated hypergeometric p values of the each biological 
process defined by the Gene Ontology Consortium http://www.geneontol 
ogy.org. In Table 1D, 9 components from the Molecular Function GO cat-
egory were selected to show the actual genes involved.
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Supplementary Tables 2. Genes that showed significant (p < 0.001) dif-
ferences in expression between rapid-forming plasma cell tumors (ABPC 
and ABLMYCPC) and slow-forming plasma cell tumors (TEPC, IL6PC 
and KiPC). Supplementary Table 2A. Genes that showed more than 2-
fold higher expression in rapid-forming plasma cell tumors than in slow-
forming plasma cell tumors. Supplementary Table 2B. Genes that showed 
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genes that showed significant (p < 0.001) differences in expression 
between rapid- and slow-forming plasma cell tumors.
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Supplementary Figure 1. Quantitative RT-PCR of relative mRNA content 
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Results of quantitative RT-PCR validation of relative mRNA content in 
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"housekeeping" gene, GAPDH.
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Supplementary Tables 3. Genes with significant (p < 0.001) differences 
in gene expression associated with site of chromosomal translocation in 
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cant differences in expression between ABPCs with T(12;15) and ABPCs 
with T(6;15). Supplementary Table 3B. Genes that showed significant 
differences in expression between TEPCs with T(12;15 class I) and TEPC 
T(12;15 class II) chromosome translocations. Two tables showing lists of 
genes that showed significant (p < 0.001) differences in expression 
between similar subclasses of plasma cell tumors that differ in site of Myc-
activating chromosomal translocation.
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Supplementary Figure 2. Meta-analysis of global gene expression of 67 
mouse samples (including 5 different subgroups of plasma cell tumors and 
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derived from a meta-analysis of a combination of expression data from 
human and mouse plasma cell dyscrasias.
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